Skip to main content
. 2023 Oct 19;6(4):729–747. doi: 10.20517/cdr.2023.78

Table 2.

Natural compounds for anticancer drug resistance by inducing necroptosis

Compounds Origin Structure Cancer Anti-drug resistant effects Refs
Berberine Coptis chinensis Franch graphic file with name cdr-6-4-729.in.T2.110.jpg Ovarian cancer Synergizing with DDP to induce necroptosis by activating the RIP3/MLKL pathway. [69]
Bufalin Bufo bufo gargarizans Cantor graphic file with name cdr-6-4-729.in.T2.210.jpg Triple-negative breast cancer Inducing necroptosis in adriamycin-resistant triple-negative breast cancer through mediating the RIP1/ROS pathway. [65]
Gambogenic Acid Garcinia hanburyi Hook. f. graphic file with name cdr-6-4-729.in.T2.310.jpg Lung cancer Synergizing with 5-FU to induce necroptosis by increasing the expression of RIP1. [67]
Ganoderic acid T Ganoderma lucidum (Leyss.ex Fr.) Karst. graphic file with name cdr-6-4-729.in.T2.410.jpg Cervical cancer Increasing the radiosensitivity of cervical cancer by inducing necroptosis via ROS generation and increased expression of RIP and MLKL. [71]
Oridonin Isodon rubescens (Hemsley) H. Hara graphic file with name cdr-6-4-729.in.T2.510.jpg Renal carcinoma Inducing necroptosis in renal carcinoma to enhance the antitumor effects of 5-FU via ROS generation, GSH depletion, and activation of p38, ERK, and JNK. [70]

DDP: Cisplatin; ERK: signal-regulated kinase; FU: fluorouracil; GSH: glutathione; JNK: c-Jun N-terminal kinase; MLKL: mixed lineage kinase domain-like protein; RIP: receptor-interacting protein; ROS: reactive oxygen species.